Actrapid insulin + glucose

Actrapid insulin + glucose refers to a perioperative glycemic management protocol used in clinical trials conducted by Imperial College London for patients with type 2 diabetes mellitus undergoing gastric bypass surgery. The protocol involves the administration of Actrapid, a short-acting recombinant human insulin manufactured by Novo Nordisk, alongside glucose monitoring and administration via a standard sliding scale to maintain glycemic control in the immediate post-operative period. Human insulin acts as an agonist at the insulin receptor, regulating glucose metabolism by promoting glucose uptake in peripheral tissues and inhibiting hepatic glucose production. This specific combination was evaluated to establish standardized algorithms for managing insulin-requiring T2DM patients following bariatric surgery.

Brand names

Actrapid

Other names

Actrapid insulin + Glucose